Paris, France and Camberley, UK – 12 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s PROmate® COVID-19 1G (q32) Real-Time PCR test has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”).
Visit PageYear: 2022
Participations des Administrateurs / PERD
Paris, France et Camberley, Royaume-Uni – 25 mars 2022 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, annonce avoir été informé, le 25 mars 2022, que l’administrateur suivant a acheté des actions ordinaires de la société d’une valeur nominale de 1/15 € chacune (les ” actions ordinaires “)
Visit PageDirector/PDMR Shareholding
Paris, France and Camberley, UK – 25 March 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 25 March 2022, the following Director purchased ordinary shares of €1/15 each in the Company (the “Ordinary Shares”): http://novacyt.com/wp-content/uploads/2022/03/3.-Novacyt-Director-Dealings-DA-ENG.pdf
Visit Page